94 completed, 9 unknown, 6 withdrawn, 5 terminated. 117 Phase 1, 28 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 117 | Completed 94, Unknown 9, Withdrawn 6, Terminated 5, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 28 | Completed 21, Unknown 3, Withdrawn 2, Recruiting 1, Terminated 1 |
Follow Rhinitis, Allergic: new trials by email Literature Review of Rhinitis, Allergic trials Research Report on Rhinitis, Allergic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Yiqi Wenyang Sanhan Formula Combined With Acupoint Application in Patients With Combined Allergic Rhinitis and Asthma Syndrome During Remission and Yang-Deficiency Syndrome Yiqi Wenyang Sanhan Formula Combined with Acupoint Application, placebo of Yiqi Wenyang Sanhan Formula combined with acupoint application - Allergic Rhinitis With Asthma | Phase 1 | Not yet recruiting | Beijing Daxing District Hospital of Integrated Chinese and Western Medicine | 188 | 2026-09-01 | 2026-04-20 |
| Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis ITI-9001, Placebo - Allergen Immunotherapy | Phase 1 | Recruiting | Immunomic Therapeutics, Inc. | 45 | 2026-06-20 | 2026-09-25 |
| A Phase 1 Study of Cizutamig in IgE Mediated Diseases Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy | Phase 1 | Withdrawn | Candid Therapeutics | 2026-04-01 | 2026-07-22 | |
| Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers AJU-R713, R713R - Bronchial Asthma, Perennial Allergic Rhinitis | Phase 1 | Completed | AJU Pharm Co., Ltd. | 62 | 2025-12-12 | 2026-09-18 |
| Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic Rhinitis PollenVax, Placebo - Rhinitis Allergic | Phase 1 | Completed | Kazakh National Agrarian University | 30 | 2025-11-22 | 2026-06-29 |
| Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma ALUTARD SQ® Felis domesticus - Allergic Rhinitis, Allergic Asthma | Phase 1 / Phase 2 | Recruiting | University of Zurich | 36 | 2025-08-20 | 2026-03-16 |
| Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects PA9159 nasal spray solution, 80 μg one day treatment, PA9159 nasal spray solution, 160 μg one day treatment, PA9159 nasal spray solution, 320 μg one day treatment - Allergic Rhinitis | Phase 1 | Completed | Anhui Palo Alto Pharmaceuticals, Inc. | 36 | 2025-03-14 | 2026-01-15 |
| Serum sST2/ miR-223 as a Dual Biomarker for Disease Activity & Clinical Efficacy of SLIT in HDM-Induced Allergic Rhinitis Sublingual Immunotherapy (SLIT) containing HDM extracts - HDM-Induced Allergic Rhinitis | Phase 1 | Completed | Zagazig University | 54 | 2025-02-01 | 2026-02-27 |
| A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. GNR-127, 20 mcg, GNR-127, 40 mcg, GNR-127, 80 mcg - Rhinitis, Allergic, Seasonal | Phase 1 / Phase 2 | Completed | AO GENERIUM | 150 | 2024-10-07 | 2026-09-21 |
| Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis. INI-2004, Placebo - Allergic Rhinitis Due to Weed Pollen, Allergic Rhinitis | Phase 1 | Completed | Inimmune Corporation | 68 | 2023-07-04 | 2026-01-16 |
| Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis Mometasone + Azelastine, Mometasone Furoate, Azelastine Hydrochloride - Seasonal Allergic Rhinitis | Phase 1 | Terminated | Sandoz | 38 | 2023-06-08 | 2023-09-28 |
| Nasal Irrigation With Combination of 0.9% NaCl and Binahong Extract (Anredera Cordifolia) 2,5% In Allergic Rhinitis extract Binahong, Isotonic saline nasal irrigation - Allergic Rhinitis, Allergic Rhinitis Due to House Dust Mite | Phase 1 | Unknown | Gadjah Mada University | 80 | 2023-05-06 | 2024-02-28 |
| Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray Azelastine Hydrochloride/ Fluticasone propionate nasal spray, 'DYMISTA' NASAL SPRAY - Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 56 | 2023-03-24 | 2023-12-28 |
| Mechanism of EGR2 in Allergic Rhinitis EGR2 - Rhinitis, Allergic | Phase 1 | Unknown | Zu-xia Ma | 3 | 2023-01-30 | 2023-02-13 |
| A Study of Genolair in Two Dosage Forms (Solution and Lyophilisate) and Xolair® in Healthy Volunteers Genolair, solution for subcutaneous administration, 150 mg, Genolair, lyophilisate for the preparation of solution for subcutaneous administration, Xolair®, solution for subcutaneous administration, 150 mg - Allergic Asthma | Phase 1 | Completed | AO GENERIUM | 180 | 2023-01-15 | 2024-07-10 |
| To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis TQC3564 tablets, Placebo tablets, TQC3564 tablets, montelukast sodium tablets - Allergic Rhinitis | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 12 | 2022-09-14 | 2024-11-26 |
| Clinical Study of Allergic Rhinitis Therapy by Stem Cells Low dose UCMSCs, Moderate dose UCMSCs, High dose UCMSCs - Allergic Rhinitis | Phase 1 | Unknown | Yantai Yuhuangding Hospital | 18 | 2022-06-13 | 2023-03-28 |
| Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells Olfactory mucosa-derived mesenchymal stem cells, Standard treatment of type Allergic Rhinitis according to the clinical protocols, Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols - Allergic Rhinitis, Rhinosinusitis Chronic | Phase 1 / Phase 2 | Unknown | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 60 | 2022-03-01 | 2022-01-19 |
| Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract Polvac Grass+Rye, Saline 0.9% - Rhinitis, Allergic, Seasonal, Rhinitis; Allergic, With Asthma | Phase 1 / Phase 2 | Completed | University of Zurich | 60 | 2022-02-10 | 2025-05-21 |
| Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients House Dust Mite Extract, Dermatophagoides Farinae - Mite Allergy, Rhinitis, Allergic | Phase 1 | Unknown | RAPHAS | 54 | 2022-01-20 | 2024-04-10 |
Showing 20 of 117. Sign in to see all of them.
Rhinitis, Allergic, Seasonal (35) · Asthma (20) · Hypersensitivity (17) · Rhinitis, Allergic, Perennial (15) · Rhinitis (6) · Dust Mite Allergy (5) · Conjunctivitis, Allergic (4) · Dermatitis, Atopic (4) · Urticaria (4) · Nasal Obstruction (3) · Sneezing (3) · Immune System Diseases (2) · Pruritus (2) · Respiratory Hypersensitivity (2)
Nose Diseases (117) · Otorhinolaryngologic Diseases (117) · Hypersensitivity, Immediate (116) · Immune System Diseases (115) · Respiratory Hypersensitivity (115) · Respiratory Tract Diseases (115) · Rhinitis (111) · Hypersensitivity (100) · Bronchial Diseases (20) · Lung Diseases (20) · Lung Diseases, Obstructive (20) · Infections (9) · Respiratory Tract Infections (8) · Skin Diseases (7)
Fluticasone (6) · azelastine (5) · Saline Solution (4) · Sodium Chloride (4) · Mometasone Furoate (3) · Sublingual Immunotherapy (3) · AZD8848 (2) · Allergens (2) · Beclomethasone (2) · Nasal Sprays (2) · Omalizumab (2) · Oxymetazoline (2) · Therapeutics (2) · bilastine (2) · montelukast (2)
GlaxoSmithKline (6) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Stallergenes Greer (5) · Gachon University Gil Medical Center (3) · Novartis (3) · Pfizer (3) · University of North Carolina, Chapel Hill (3) · AO GENERIUM (2) · Allergy Therapeutics (2) · Anergis (2) · Anhui Palo Alto Pharmaceuticals, Inc. (2) · AstraZeneca (2) · Faes Farma, S.A. (2) · Gilead Sciences (2) · HAL Allergy (2)
United States (32) · South Korea (10) · Germany (8) · United Kingdom (8) · Canada (6) · China (6) · Australia (5) · Sweden (4) · Switzerland (4) · Austria (3) · Japan (3) · Denmark (2) · Netherlands (2) · Russia (2) · Belgium (1)
Robert Wood, MD (4) · Christine Kolb (2) · David Peden, MD (2) · Francois Spertini, MD (2) · Friedrich Horak, MD (2) · Oksana A. Markova, MD (2) · Sang Min Lee, M.D., Ph.D. (2) · Stephen J Pollard, MD (2) · Alicia T Widge, M.D. (1) · Amber M Patterson, MD (1)
PMID 24184147, PMID 19001265, PMID 22464647, PMID 19680119, PMID 22726593, PMID 23374268, PMID 24035151, PMID 26706294, PMID 10831441, PMID 11069570, PMID 11297958, PMID 11468003, PMID 15379842, PMID 16553814, PMID 17083353, PMID 19647862, PMID 19717725, PMID 20921983, PMID 21642470, PMID 21725898, PMID 22393898, PMID 22621776, PMID 23181790, PMID 23725004, PMID 24105252, PMID 24261946, PMID 24439076, PMID 24934402, PMID 24986270, PMID 24990880, PMID 25149431, PMID 26044169, PMID 26342289, PMID 26553448, PMID 26843086, PMID 26915677, PMID 27231527, PMID 27253988, PMID 27357167, PMID 27677865, PMID 28911971, PMID 30391954, PMID 30881050, PMID 32679209, PMID 32926419, PMID 33099797, PMID 33647073, PMID 34088322, PMID 34187620, PMID 34429875
2009 (2), 2014 (1), 2023 (1)